-
公开(公告)号：US09822150B2
公开(公告)日：2017-11-21
申请号：US14470922
申请日：2014-08-27
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Rasappa Gounder Arumugham , John Erwin Farley , Leah Diane Fletcher , Shannon Harris , Kathrin Ute Jansen , Thomas Richard Jones , Lakshmi Khandke , Bounthon Loun , John Lance Perez , Gary Warren Zlotnick
IPC: A61K39/00 , C07K14/22 , A61K39/095 , A61K39/12 , A61K39/39 , C12N7/00 , A61K39/13 , A61K39/295
CPC classification number: C07K14/22 , A61K39/0016 , A61K39/095 , A61K39/12 , A61K39/13 , A61K39/295 , A61K39/39 , A61K2039/5252 , A61K2039/545 , A61K2039/55505 , A61K2039/55511 , A61K2039/70 , C12N7/00 , C12N2710/20034 , C12N2770/32634 , Y02A50/466
Abstract: In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.
-
公开(公告)号：US09724402B2
公开(公告)日：2017-08-08
申请号：US15237005
申请日：2016-08-15
Applicant: PFIZER INC.
Inventor： Annaliesa Sybil Anderson , Susan Kay Hoiseth , Kathrin Ute Jansen , Justin Keith Moran , Mark E. Ruppen
IPC: A61K39/095 , C07K14/22 , C07K16/12 , A61K39/00
CPC classification number: A61K39/095 , A61K2039/55577 , A61K2039/6018 , C07K14/22 , C07K16/1217
Abstract: In one aspect, the invention relates to an isolated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 71 in another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup.
-
43.发明公开公开(公告)号：US20240189410A1
公开(公告)日：2024-06-13
申请号：US18535116
申请日：2023-12-11
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Marina A. Gonzalez-Garis , Lei Hu , Isis Kanevsky , Paul Arthur Liberator , Justin Keith Moran , Lynn Marie Phelan , Michael William Pride , Shuai Shi , Naveen Surendran
CPC classification number: A61K39/08 , A61K39/39 , A61P31/04 , A61K2039/55561
Abstract: The present invention relates to immunogenic compositions that comprise a Clostridioides difficile toxoid A and/or a C. difficile toxoid B, and an adjuvant, and methods of use thereof. The present invention further relate to a methods for eliciting an enhanced immune response in a human against a C. difficile infection. The methods include administering to the human an effective dose of an immunogenic composition, which includes a C. difficile toxoid and an adjuvant, wherein the composition is administered two times.
-
公开(公告)号：US11952597B2
公开(公告)日：2024-04-09
申请号：US16922952
申请日：2020-07-07
Applicant: Pfizer Inc.
Inventor： Jason Arnold Lotvin , Annaliesa Sybil Anderson , Robert G. K. Donald , Michael James Flint , Narender Kumar Kalyan , Kathrin Ute Jansen , Maninder K. Sidhu , Justin Keith Moran , Mark Edward Ruppen , Weiqiang Sun
CPC classification number: C12N9/1051 , C07K14/33 , C12N1/20
Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.
-
公开(公告)号：US20240000912A1
公开(公告)日：2024-01-04
申请号：US18034239
申请日：2021-11-01
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Seema Shridhar Gangolli , Kathrin Ute Jansen , Avvari Krishna Prasad , Michael William Pride , Ingrid Lea Scully , Wendy Jo Watson
CPC classification number: A61K39/092 , A61P31/04 , A61K2039/70
Abstract: An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 15, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said immunogenic compositions.
-
Patent Agency Ranking
公开(公告)号：US20210024903A1
公开(公告)日：2021-01-28
申请号：US16922952
申请日：2020-07-07
Applicant: Pfizer Inc.
Inventor： Jason Arnold Lotvin , Annaliesa Sybil Anderson , Robert G. K. Donald , Michael James Flint , Narender Kumar Kalyan , Kathrin Ute Jansen , Maninder K. Sidhu , Justin Keith Moran , Mark Edward Ruppen , Weiqiang Sun
Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.
-
公开(公告)号：US10899802B2
公开(公告)日：2021-01-26
申请号：US15728610
申请日：2017-10-10
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Rasappa Gounder Arumugham , John Erwin Farley , Leah Diane Fletcher , Shannon Lea Harris , Kathrin Ute Jansen , Thomas Richard Jones , Lakshmi Khandke , Bounthon Loun , John Lance Perez , Gary Warren Zlotnick
IPC: C07K14/22 , A61K39/00 , C12N7/00 , A61K39/13 , A61K39/295 , A61K39/095 , A61K39/12 , A61K39/39
Abstract: In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.
-
公开(公告)号：US20200368340A1
公开(公告)日：2020-11-26
申请号：US16984499
申请日：2020-08-04
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Leena Shriram Bagle , Amardeep Singh Bhupender Bhalla , Miguel Angel Garcia , Lei Hu , Lakshmi Khandke , Avvari Krishna Prasad , Cindy Xudong Yang
Abstract: The invention relates to immunogenic compositions comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.
-
公开(公告)号：US10751402B2
公开(公告)日：2020-08-25
申请号：US15800373
申请日：2017-11-01
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Leena Shriram Bagle , Amardeep Singh Bhupender Bhalla , Miguel Angel Garcia , Lei Hu , Lakshmi Khandke , Avvari Krishna Prasad , Cindy Xudong Yang
Abstract: The invention relates to immunogenic compositions comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.
-
公开(公告)号：US20200061177A1
公开(公告)日：2020-02-27
申请号：US16534457
申请日：2019-08-07
Applicant: Pfizer Inc.
Inventor： Robert G.K. Donald , Annaliesa Sybil Anderson , Laurent Oliver Chorro , Jianxin Gu , Jin-Hwan Kim , Srinivas Kodali , Jason Arnold Lotvin , Justin Keith Moran , Rosalind Pan , Avvari Krishna Prasad , Mark Edward Ruppen , Suddham Singh , Ling Chu , Scott Ellis Lomberk , Karen Kiyoko Takane , Nishith Merchant , Wei Chen
IPC: A61K39/108 , C08B37/00 , A61P37/04 , A61P31/04
Abstract: In one aspect, the invention relates to an immunogenic composition comprising modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof. Multivalent vaccines may be prepared by combining two or more monovalent immunogenic compositions for different E. coli serotypes. In one embodiment, the modified O-polysaccharide molecules are produced by a recombinant bacterium that includes a wzz gene.
-
-
-
-
-
-
-
-
-
Search Results
76
records
(took 0.023 seconds)
